EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Long-Term Impact of Diabetic Retinopathy on Response to Anti-VEGF Treatment in Neovascular AMD

Giacomo Boscia, Daniela Bacherini, Stela Vujosevic, Maria Oliva Grassi, Enrico Borrelli, Ermete Giancipoli, Luca Landini, Mariagrazia Pignataro, Giovanni Alessio, Francesco Boscia, Pasquale Viggiano

Investigative Ophthalmology & Visual Science · 2024-08-02 · 65 (10) · 6

DOI: 10.1167/iovs.65.10.6 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, published on 2024-08-02. Written by Giacomo Boscia and 10 co-authors. Institution: Department of Translational Biomedicine Neuroscience, University of Bari "Aldo Moro," Bari, Italy. Major MEDLINE topics: Diabetic Retinopathy, Angiogenesis Inhibitors, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A. Cited 18 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Purpose

To explore the long-term effect of diabetic retinopathy on response to anti-vascular endothelial growth factor (VEGF) treatment in age-related macular degeneration-associated type 1 macular neovascularization (MNV) using optical coherence tomography angiography (OCTA).

Methods

A total of 45 eyes with exudative neovascular age-related macular degeneration (nAMD) with type 1 MNV were included in the analysis. Among them, 24 eyes of 24 patients had no history of diabetes mellitus (DM) in their anamnesis and were assigned to the Not Diabetic group; 21 eyes of 21 patients had mild diabetic retinopathy and were included in the Diabetic group. We considered the following outcome measures: (1) best-corrected visual acuity changes; (2) central macular thickness; (3) MNV lesion area; and (4) MNV flow area. The OCTA acquisitions were performed at the following time points: (1) baseline visit, which corresponded to the day before the first injection; (2) post-loading phase (LP), which was scheduled at 1 month after the last LP injection; and (3) 12-month follow-up visit.

Results

All morphofunctional parameters showed a significant improvement after the LP and at the 12-month follow-up visit. Specifically, both the Diabetic group and the Not Diabetic group displayed a significant reduction of MNV lesion areas at both the post-LP assessment (P = 0.026 and P = 0.016, respectively) and the 12-month follow-up (P = 0.039 and P = 0.025, respectively). Similarly, the MNV flow area was significantly decreased in both the Diabetic group and the Not Diabetic group at the post-LP assessment (P 0.05).

Conclusions

Our results indicated that the Diabetic group exhibited a smaller reduction in MNV lesion area after 12 months of anti-VEGF treatment. This highlights the importance of considering diabetic retinopathy as a potential modifier of treatment outcomes in nAMD management, with DM serving as a crucial risk factor during anti-angiogenic treatment.

Subjects

MeSH terms (MEDLINE)

Diabetic RetinopathyAngiogenesis InhibitorsTomography, Optical CoherenceVascular Endothelial Growth Factor AIntravitreal InjectionsVisual AcuityFluorescein AngiographyWet Macular DegenerationHumansMaleFemaleAgedFollow-Up StudiesMiddle AgedRanibizumabBevacizumabRetrospective StudiesReceptors, Vascular Endothelial Growth FactorTreatment OutcomeFundus OculiTime FactorsRecombinant Fusion Proteins

Substances

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumabBevacizumabReceptors, Vascular Endothelial Growth FactorVEGFA protein, humanafliberceptRecombinant Fusion Proteins

Authors and institutions

  • Department of Translational Biomedicine Neuroscience, University of Bari "Aldo Moro," Bari, Italy.
  • Ophthalmology Department, Careggi University Hospital, University of Florence, Florence, Italy.
  • Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
  • Eye Clinic IRCCS MultiMedica, Milan, Italy.
  • Department of Surgical Sciences, University of Turin, Turin, Italy.
  • Department of Ophthalmology, University of Foggia, Foggia, Italy.

Cite

APA

Boscia, G., Bacherini, D., Vujosevic, S., Grassi, M. O., Borrelli, E., Giancipoli, E., Landini, L., Pignataro, M., Alessio, G., Boscia, F., & Viggiano, P. (2024). Long-Term Impact of Diabetic Retinopathy on Response to Anti-VEGF Treatment in Neovascular AMD. Investigative Ophthalmology & Visual Science, 65(10), 6. https://doi.org/10.1167/iovs.65.10.6

Vancouver

Boscia G, Bacherini D, Vujosevic S, Grassi MO, Borrelli E, Giancipoli E, et al. Long-Term Impact of Diabetic Retinopathy on Response to Anti-VEGF Treatment in Neovascular AMD. Investigative Ophthalmology & Visual Science. 2024;65(10):6. doi:10.1167/iovs.65.10.6

BibTeX
@article{Boscia2024,
  author = {Boscia, Giacomo and Bacherini, Daniela and Vujosevic, Stela and Grassi, Maria Oliva and Borrelli, Enrico and Giancipoli, Ermete and Landini, Luca and Pignataro, Mariagrazia and Alessio, Giovanni and Boscia, Francesco and Viggiano, Pasquale},
  title = {Long-Term Impact of Diabetic Retinopathy on Response to Anti-VEGF Treatment in Neovascular AMD},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2024},
  volume = {65},
  number = {10},
  pages = {6},
  doi = {10.1167/iovs.65.10.6}
}
Start for free →